Strategies for optimizing combinations of molecularly targeted anticancer agents

被引：283

作者：

Dancey, Janet E. ^{[1
]}

Chen, Helen X. ^{[1
]}

机构：

[1] NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, Rockville, MD 20852 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 08期

关键词：

D O I：

10.1038/nrd2089

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The rapid emergence of hundreds of new agents that modulate an ever-growing list of cancer-specific molecular targets offers tremendous hope for cancer patients. However, evaluating targeted agents individually, in combination with standard treatments, and in combination with other targeted agents presents significant development challenges. Because the number of possible drug combinations is essentially limitless, a strategy for determining the most promising combinations and prioritizing their evaluation is crucial. Here, we consider the crucial elements of a development strategy for targeted-agent combinations. Issues that pose challenges to the rational preclinical and clinical evaluation of such combinations will be described, and possible approaches to overcoming these challenges will be discussed.

引用

页码：649 / 659

页数：11

共 63 条

[1] Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma [J].

Abd El-Rehim, DM ;

Pinder, SE ;

Paish, CE ;

Bell, JA ;

Rampaul, RS ;

Blamey, RW ;

Robertson, JFR ;

Nicholson, RI ;

Ellis, IO .

BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1532-1542

[2]

ALBAIN KS, 2002, P ASCO, V21, P143

[3] Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer [J].

Baselga, J ;

Albanell, J ;

Ruiz, A ;

Lluch, A ;

Gascón, P ;

Guillém, V ;

González, S ;

Sauleda, S ;

Marimón, I ;

Tabernero, JM ;

Koehler, MT ;

Rojo, F .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5323-5333

[4] EGFR gene amplification in breast cancer:: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations [J].

Bhargava, R ;

Gerald, WL ;

Li, AR ;

Pan, QL ;

Lal, P ;

Ladanyi, M ;

Chen, BY .

MODERN PATHOLOGY, 2005, 18 (08) :1027-1033

[5] ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study [J].

Bianchi, S ;

Palli, D ;

Falchetti, M ;

Saieva, C ;

Masala, G ;

Mancini, B ;

Lupi, R ;

Noviello, C ;

Omerovic, J ;

Paglierani, M ;

Vezzosi, V ;

Alimandi, M ;

Mariani-Costantini, R ;

Ottini, L .

JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 206 (03) :702-708

[6] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].

Bonner, JA ;

Harari, PM ;

Giralt, J ;

Azarnia, N ;

Shin, DM ;

Cohen, RB ;

Jones, CU ;

Sur, R ;

Raben, D ;

Jassem, J ;

Ove, R ;

Kies, MS ;

Baselga, J ;

Youssoufian, H ;

Amellal, N ;

Rowinsky, EK ;

Ang, KK .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578

[7] Systematic discovery of multicomponent therapeutics [J].

Borisy, AA ;

Elliott, PJ ;

Hurst, NW ;

Lee, MS ;

Lehár, J ;

Price, ER ;

Serbedzija, G ;

Zimmermann, GR ;

Foley, MA ;

Stockwell, BR ;

Keith, CT .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (13) :7977-7982

[8]

Britten CD, 2004, J CLIN ONCOL, V22, p206S

[9] Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study [J].

Burtness, B ;

Goldwasser, MA ;

Flood, W ;

Mattar, B ;

Forastiere, AA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8646-8654

[10] Drug combinations: From laboratory to practice [J].

Chou, TC .

JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 132 (01) :6-8

← 1 2 3 4 5 6 7 →